Ziqi Zhuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ziqi Zhuang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Gang Liu
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen China
2 shared publications - Peiyu Wang
State Key Laboratory of Vaccines for Infectious Diseases Center for Molecular Imaging and Translational Medicine Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research School of Public Health Xiamen University Xiamen China
2 shared publications - Changhong Li
State Key Laboratory of Cellular Stress Biology Innovation Center for Cell Biology School of Life Sciences Xiamen University Xiamen 361102 China
1 shared publication - Chao Liu
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China
1 shared publication - Chengchao Chu
Xiamen University
1 shared publication Chenhao Zhang
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaeb5894
Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity
Cancer immunotherapy remains limited by insufficient antigen presentation and immunosuppressive tumor microenvironment. Here, we present a vaccine strategy based on cold atmospheric plasma (CAP)–engineered tumor cell–derived immune reprogramming nanovesicles (CAPTURE) that integrates spatiotemporal sequential immunization to potentiate antitumor immunity. CAPTURE is engineered from tumor cells pretreated with CAP, which up-regulates major histocompatibility complex class I expression via p62-mediated autophagy to promote full-spectrum epitope antigen presentation, and surface-functionalized anti-CD28 (αCD28) on CAPTURE provides costimulatory signals to directly activate T cells through αCD28-CD28, bypassing B7-CTLA-4–mediated T cell inhibition. Under spatiotemporal sequential immunity, CAPTURE exhibits homologous tumor targeting and lymph node accumulation, enhancing antigen presentation for CD8 + T cell activation and tumor immunogenic remodeling. In mouse models, CAPTURE achieved near-complete tumor suppression, driven by amplified cytotoxic T cell responses, increased T cell clonal diversity, and CXCR3-mediated tumor infiltration. This study presents a universal biomimetic nanovaccine strategy that can reshape both T cells’ immunity and tumor cells’ immunogenicity, induce broad-spectrum immune responses to overcome immune evasion, and offer unique insights and innovative technologies for precision cancer immunotherapy.
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaeb5894
Open AccessCold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity
Cancer immunotherapy remains limited by insufficient antigen presentation and immunosuppressive tumor microenvironment. Here, we present a vaccine strategy based on cold atmospheric plasma (CAP)–engineered tumor cell–derived immune reprogramming nanovesicles (CAPTURE) that integrates spatiotemporal sequential immunization to potentiate antitumor immunity. CAPTURE is engineered from tumor cells pretreated with CAP, which up-regulates major histocompatibility complex class I expression via p62-mediated autophagy to promote full-spectrum epitope antigen presentation, and surface-functionalized anti-CD28 (αCD28) on CAPTURE provides costimulatory signals to directly activate T cells through αCD28-CD28, bypassing B7-CTLA-4–mediated T cell inhibition. Under spatiotemporal sequential immunity, CAPTURE exhibits homologous tumor targeting and lymph node accumulation, enhancing antigen presentation for CD8 + T cell activation and tumor immunogenic remodeling. In mouse models, CAPTURE achieved near-complete tumor suppression, driven by amplified cytotoxic T cell responses, increased T cell clonal diversity, and CXCR3-mediated tumor infiltration. This study presents a universal biomimetic nanovaccine strategy that can reshape both T cells’ immunity and tumor cells’ immunogenicity, induce broad-spectrum immune responses to overcome immune evasion, and offer unique insights and innovative technologies for precision cancer immunotherapy.
- 10 July 2023
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 15 (28) , 11813-11833
A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy
The multi-modal therapy has superior anti-tumor efficacy to the uni-modal using nanoparticles inducing reactive oxygen species (ROS). The multi-component nature of cold atmospheric plasma (CAP) enables multi-modal excitation with a single treatment.
- 10 July 2023
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 15 (28) , 11813-11833
A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy
The multi-modal therapy has superior anti-tumor efficacy to the uni-modal using nanoparticles inducing reactive oxygen species (ROS). The multi-component nature of cold atmospheric plasma (CAP) enables multi-modal excitation with a single treatment.